Relief Therapeutics

AdVita Lifescience focuses on developing diagnostic and pharmaceutical technologies aimed at enhancing the therapy and diagnosis of rare lung diseases. The company offers a range of products designed to detect conditions such as sarcoidosis and related disorders. In addition to its human medicine initiatives, AdVita Lifescience also engages in the development of products for veterinary medicine, reflecting a broad commitment to addressing lung health across species. Through its innovative approaches, the company aims to improve patient outcomes and advance the understanding of rare lung conditions.

APR Applied Pharma Research s.a. is a pharmaceutical company based in Balerna, Switzerland, specializing in the identification, development, manufacturing, and licensing of healthcare products across various therapeutic areas. Founded in 1990, the company focuses on creating oral and topical formulations, including prescription and over-the-counter pharmaceuticals, nutraceuticals, dermocosmetics, and medical devices. Its innovative drug delivery systems cater to a wide range of applications, addressing conditions such as cancer supportive care, CNS disorders, dermatology, gynecology, and pain management, among others. APR is particularly dedicated to meeting the needs of patients with rare diseases and aims to enhance healthcare outcomes through patient-centric solutions. The company has a strategic focus on markets in Europe and the United States, as well as emerging markets like China, Russia, and Latin America, ensuring a broad reach for its products and services.

FirstString Research, Inc. is a clinical-stage biopharmaceutical company based in Mount Pleasant, South Carolina, that focuses on developing therapies for inflammation-based medical conditions. Founded in 2005, the company specializes in translating cell-cell communication and adhesion science into innovative drug applications aimed at scar prevention, inflammation reduction, wound healing, and complex tissue regeneration. FirstString holds an exclusive worldwide license for its connexin-technology platform and a portfolio of peptides that modulate junctional proteins essential for inter-cellular communication. The company has demonstrated the safety and efficacy of its lead peptide in a Phase I human clinical trial and is currently advancing Granexin Gel, a topical formulation derived from this peptide, through three Phase II clinical trials targeting scar reduction and chronic wound treatment. FirstString Research has a strategic collaboration with Relief Therapeutics SA and operates as a subsidiary of Relief Therapeutics Holding AG.